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There are few in vitro models of exocrine pancreas development and primary human pancreatic adenocarcinoma (PDAC). We establish three-dimensional culture conditions to induce the differentiation of human pluripotent stem cells into exocrine progenitor organoids that form ductal and acinar structures in culture and in vivo. Expression of mutant KRAS or TP53 in progenitor organoids induces mutation-specific phenotypes in culture and in vivo. Expression of TP53 R175H induces cytosolic SOX9 localization. In patient tumors bearing TP53 mutations, SOX9 was cytoplasmic and associated with mortality. We also define culture conditions for clonal generation of tumor organoids from freshly resected PDAC. Tumor organoids maintain the differentiation status, histoarchitecture and phenotypic heterogeneity of the primary tumor and retain patient-specific physiological changes, including hypoxia, oxygen consumption, epigenetic marks and differences in sensitivity to inhibition of the histone methyltransferase EZH2. Thus, pancreatic progenitor organoids and tumor organoids can be used to model PDAC and for drug screening to identify precision therapy strategies.
Patients diagnosed with locally advanced or metastatic pancreatic cancers have a 5-year survival rate of less than 3%. Late presentation and high mortality highlight a need for early detection methods and new treatment strategies. More than 95% of pancreatic cancers originate from the exocrine compartment, which comprises acinar and ductal cells 1, 2 . The cellular origins of human pancreatic ductal adenocarcinoma (PDAC) are poorly understood. Dysregulation of KRAS, CDKN2A, TP53 and SMAD4 are frequently associated with PDAC 3 . Neither the biological changes associated with precancerous lesions (such as pancreatic intraepithelial neoplasia (PanIN)) nor their progressions to PDAC are well understood. Progenitors isolated from the mouse pancreas and grown in organoid cultures have been used to investigate normal ductal morphogenesis and model early disease [4] [5] [6] . However, there is a lack of culture models for understanding mechanisms associated with initiation and progression of human PDAC.
Several studies have shown that human pluripotent stem cells (PSCs) can be committed toward the pancreatic endocrine lineage to generate insulin-producing beta cells [7] [8] [9] . PSCs differentiated toward the exocrine lineage to generate ductal and acinar cells can be used to model normal development in culture. Here we report conditions for inducing exocrine differentiation of PSC-derived pancreatic progenitors and for growing primary human PDAC as tumor organoids in threedimensional (3D) culture. The tumor organoids can be clonally derived and recreate histoarchitectural heterogeneity observed in matched tumors. Using progenitor organoids, we identify changes in localization of the transcription factor SOX9 as a clinically relevant phenotype associated with mutant p53 (encoded by TP53) expression. In addition, we use tumor organoids to identify patient-specific differences in EZH2 dependency and biology.
RESULTS

Induction of polarized organoids from human PSCs
Ductal and acinar lineages develop from NKX6.1 + PDX1 + progenitors in vivo 10 . We plated a PSC-derived pancreatic lineage-committed population containing NKX6.1 + PDX1 + cells (Supplementary Fig. 1a ) in 3D culture and screened it for growth factors and nutrients critical for pancreas development 11, 12 . A combination of factors including FGF2, insulin, hydrocortisone, ascorbic acid, all-transretinoic acid Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell-and patient-derived tumor organoids and B27 serum-free supplement induced polarized 3D structures from 10-20% of PSC-derived cells (Fig. 1a) . Those that did not form structures died during the process.
Structures were mostly clonally derived (Supplementary Fig. 1b ) and comprised one layer of polarized epithelia surrounding a hollow central lumen (Fig. 1b,c) . Cells also secreted basement membrane, as assessed with antibodies specific to human collagen IV and laminin-α5 (Fig. 1c) . Tight junctions, basement membrane and apical microvilli were detected by transmission electron microscopy ( Fig. 1d) . Karyotyping confirmed that these cells had normal diploid genomes (Supplementary Fig. 1c) .
Cell proliferation and control of organ size are important for normal tissue morphogenesis. The progenitor organoids showed substantial increases in size and were highly proliferative until day 12 in 3D culture ( Fig. 1e and Supplementary Fig. 1d,e) . By day 14, >95% of organoids were proliferation arrested with a diameter range of 30-200 µm (Supplementary Fig. 1d,e) .
Consistent with the finding that apoptosis is not required during lumen formation in embryonic pancreatic ducts in vivo 13 , we detected little cleaved caspase 3 in the organoids ( Fig. 1f and  Supplementary Fig. 1f ). Apical-basal polarity was established starting at day 8, as monitored by immunostaining to detect glycoprotein mucin 1 (MUC1), the apical marker tight junction protein-1 (ZO-1) and the basal marker collagen IV (Fig. 1f) . Day 16 organoids can be serially passaged (tested to passage 5) to reinitiate organogenesis (Supplementary Fig. 1g ). These organoids maintained size control, had hollow lumens and apical-basal polarity (Fig. 1g) .
Organoids express exocrine pancreatic progenitor cell markers Global gene-expression analysis and unsupervised clustering placed 3D organoids branch proximal to human pancreas than endodermal cells or a human mammary epithelial cell line (MCF-10A) (Supplementary Fig. 2a) . Expression of pancreas-specific markers (NKX6.1 and PTF1A) was significantly higher in 3D organoids than in endoderm-derived organs (Fig. 2a) . By contrast, expression of markers for liver (albumin and CREBPA), stomach (SOX2) and duodenum (CDX2) was significantly lower in both human pancreas tissue and 3D organoids than in respective organs (Fig. 2b) .
We monitored expression of transcription factors that are expressed in a cell type-specific manner within the pancreas 10, 14, 15 (Fig. 2c) . Organoids expressed higher levels of progenitor cell markers (PDX1, NKX6.1) and lower levels of islet cell markers (NKX2.2) than did fetal and adult pancreas and lower levels of the acinar marker GATA4 than did adult pancreas (Fig. 2d,e) . We next analyzed expression of these markers by immunofluorescence. PDX1, SOX9 and NKX6.1 were expressed in the majority of organoids (Fig. 2f) . PDX1 protein expression was heterogeneous in each organoid (Fig. 2f) . All cells within organoids expressed pancreatic epithelium-associated cytokeratin 19 (KRT19) (Supplementary Fig. 2b ). We observed a 3.5-fold increase in SOX9 expression beginning on day 6 and low NGN3 expression, indicating that our conditions promoted exocrine lineage specification and suppressed endocrine lineage commitment (Supplementary Fig. 2c ). Expression of pancreatic progenitor markers PDX1 and PTF1A was constant from day 2 to day 16. We next examined whether the organoids expressed markers associated with differentiated acinar, ductal or islet cells. Expression of ductal (CA2 and CFTR), acinar (CEL, PNLIP and SPINK) and islet (insulin and glucagon) cell markers were either undetectable in organoids or lower (in the case of CA2) than in adult pancreas (Fig. 2g) , suggesting that these structures were not terminally differentiated and consisted largely of progenitor cells. Hereafter we refer to these structures as progenitor organoids.
Differentiation of pancreatic progenitor organoids
Because Wnt, notch, transforming growth factor-β (TGF-β) and Hedgehog pathways have been implicated in normal pancreas npg development 11, 12 , we modified our protocol (Fig. 1a) by adding steps (steps 2 and 3) to induce differentiation of progenitor organoids by modulating these pathways. For step 2, the culture medium included A8301, an inhibitor of TGF-β receptor I, and DBZ, an inhibitor of notch, and the medium for step 3 included the growth factors FGF7 and EGF ( Fig. 3a and Online Methods). This protocol induced differentiation of progenitor organoids to a population containing 10-15% CA2 + ductal and 0.5-1% CPA1 + acinar organoids, as indicated by mRNA expression of acinar and ductal markers as determined by quantitative PCR (qPCR) (Fig. 3b) .
We also tested whether the mouse mammary gland fat pad, which supports growth of pancreatic islets 16 , would induce differentiation of progenitor organoids into pancreatic exocrine structures. We injected dissociated day 16 organoids into female NOD SCID mice aged 6-8 weeks (Online Methods). Fifteen weeks after injection, more than 90% of the glands had human cell outgrowths that expressed human leukocyte antigen I (HLA I) and were morphologically distinct from endogenous mammary ductal structures (Fig. 3c) . Transplants showed similar anatomic organization to that of human fetal pancreas tissue sections 10, 17 , with CPA1 + acinar cell clusters located near KRT19 + ductal structures (Fig. 3d) , demonstrating that progenitor organoids can undergo organogenesis in vivo.
Human acinar (CPA1 and CEL) and ductal (CFTR) marker expression was higher in organoid transplants than in progenitor organoids, whereas CA2 expression was unaffected (Fig. 3e) . Organoid transplants lacked NKX6.1 but maintained SOX9 expression in vivo, as expected 10 (Fig. 3f) . Differentiated pancreatic ducts and islets, but not acini, have primary cilia 18 . In organoid transplants, we observed primary cilia in CA2 + ductal but not in CPA1 + acinar-like structures (Fig. 3g,h ). Thus, progenitor organoids can generate outgrowths with molecular and morphological characteristics of human fetal exocrine pancreas.
Pancreatic cancer modeling with progenitor organoids
Progenitor organoids may model phenotypes associated with mutations in KRAS and TP53, two of the most frequently observed alterations in PDAC 19, 20 . We infected pancreatic lineage-committed cells with lentiviral vectors expressing mCherry (control), KRAS G12V or the dominant-negative mutant TP53 R175H . Organoids transduced with KRAS G12V and TP53 R175H expressed detectable levels of their respective transgenes ( Supplementary Fig. 3a ,b) and were larger and had more cells per structure than mCherry-transduced organoids (Fig. 4a,b) . Unlike KRAS G12V -transduced organoids, organoids transduced with TP53 R175H showed low proliferation rates by day 16 (Fig. 4b,c) .
Form-factor analysis indicated that organoids transduced with KRAS G12V or TP53 R175H were disorganized as compared to those transduced with mCherry ( Fig. 4d) . KRAS G12V -expressing organoids showed cystic organization with apically positioned nuclei and a morphology consistent with early pancreatic tumor lesions (Fig. 4e) , whereas TP53 R175H -expressing organoids showed atypical organization with apically positioned nuclei and filled lumens (Fig. 4e) .
After 16 d in culture, organoids were injected into 8-10 mammary fat pads of NOD SCID mice; 22 weeks later, we confirmed by Gene on Gene off P r o g e n it o r o r g a n o id P r o g e n it o r o r g a n o id P r o g e n it o r o r g a n o id P r o g e n it o r o r g a n o id P r o g e n it o r o r g a n o id P r o g e n it o r o r g a n o id P r o g e n it o r o r g a n o id P r o g e n it o r o r g a n o id P a n c r e a s P a n c r e a s P a n c r e a s npg immunostaining for HLA I and transgene expression that the structures that grew were of human origin (Fig. 4f) . mCherry-transduced organoid-derived outgrowths showed normal ductal organization, whereas outgrowths transduced with KRAS G12V or TP53 R175H showed abnormal ductal architecture and nuclear morphology consistent with neoplastic transformation (Supplementary Fig. 3c,d) . Thus, in culture and in vivo, progenitor organoids can serve as models for investigating early stages of transformation.
Cytoplasmic SOX9, TP53 status and clinical outcome We next investigated changes in the expression of differentiation markers in organoids transduced with KRAS G12V and TP53 R175H . Among the markers analyzed, SOX9 was localized in the cytoplasm in TP53 R175H but not in mCherry or KRAS G12V organoids (Fig. 5a,b) . In breast cancer, cytoplasmic SOX9 is a marker of poor prognosis 21, 22 . We therefore investigated SOX9 localization in normal human pancreas and PDAC. In normal pancreas samples (N = 4) SOX9 was localized in the nucleus, whereas in p53-expressing (indicating accumulation of mutant p53) PDAC SOX9 was localized in the cytoplasm (Fig. 5c) .
To understand the clinical relevance of this observation, we analyzed two sets of PDAC samples from independent cohorts (cohort I, N = 98; cohort II, N = 242) for SOX9 localization and TP53 mutation status. Among the PDAC samples with nuclear SOX9 (N = 35), 77% were p53 negative; of samples with cytoplasmic SOX9 (N = 26), 81% were p53 positive; the association between TP53 status and SOX9 localization was significant (P = 3.25 × 10 −5 ) (Fig. 5d) .
In addition, in cohort I, cytoplasmic SOX9 was significantly associated with poor disease-free survival (DFS) and overall survival (OS) (DFS, P = 0.035; OS, P = 0.0072) (Fig. 5e) . In cohort II, cytoplasmic SOX9 was associated with higher tumor grade (P = 0.0485) and worse disease-specific survival than was nuclear SOX9 (P = 0.0420) ( Fig. 5f and Supplementary Table 1) .
Tumor organoids conserve phenotypic heterogeneity As PDAC originates from the exocrine lineage, we reasoned that our culture conditions might be adapted for growing primary pancreatic tumors. We obtained 20 primary tumor samples from surgical resections (Online Methods) to establish organoid cultures. Tumor organoids were established for 17 of the 20 samples; the 17 that grew were PDAC and the three that did not were poorly-to-moderately differentiated PDAC and intraductal papillary mucinous cystic neoplasms (Supplementary Table 2) . Time-lapse phase-contrast imaging of organoid culture UHN17 (derived from University Health Network pancreatic cancer patient 17) Fig. 4a ) showed that many organoids were clonally derived. Time-lapse imaging of another culture, UHN6 (Fig. 6a) , showed dynamic organoid behavior, with structures moving and merging and cells dispersing from an organoid (Supplementary Video 1) . We analyzed the histoarchitecture and differentiation status of the tumor organoids after 16 d in 3D culture. Tumor organoids showed similar morphological and cytological features to those of the primary tumors they were derived from (Fig. 6b) , as well as similar expression of differentiation markers, including KRT19, GATA6, and SOX9 (Fig. 6b,c) . None of the tumors or organoids expressed islet (NKX6.1) or acinar (GATA4) cell markers (Supplementary Fig. 4b ).
To determine whether tumor organoids can be serially passaged and form tumors in vivo, we analyzed organoid-forming efficiencies and growth rates in PDAC samples from three patients. All samples effectively established serial cultures and maintained similar growth rates during assay periods (Supplementary Fig. 4c) . The low organoid-forming efficiency of UHN17 in passage 3, an indirect consequence of individual organoids moving and merging to form large structures (Supplementary Fig. 4c ). Tumor organoids could be frozen and thawed to re-establish cultures maintaining phase and morphology (assessed by hematoxylin and eosin (H&E) staining) across passages (Supplementary Fig. 4d ). To test whether the tumor organoids could generate tumors in xenograft models, we subcutaneously injected 50,000 cells from two independent organoid cultures ( Supplementary Fig. 4e and data not shown) into NSG mice (6 sites per organoid culture). All injections resulted in tumor growth within 4-7 weeks. The xenograft tumors maintained the histoarchitectures present in the primary tumors from which the organoids were derived and could be used to re-establish organoid cultures (Supplementary Fig. 4e) .
Carcinomas display intratumoral spatial histological heterogeneity 23 , which was maintained in our tumor organoid system. For example, primary tumor UHN17 showed two distinct populations of invasive glands: one composed of larger tall columnar cells with cleared granular cytoplasm and one of smaller cuboidal cells with deeply eosinophilic cytoplasm. Organoids generated from this primary tumor recapitulated these morphologically distinct populations (Fig. 6d) . Thus, tumor organoids conserve histological organization, differentiation status and morphologic heterogeneity observed in primary PDACs, a property we refer to as 'histostasis' .
Tumor organoids as platforms for personalized drug testing
Despite the availability of multiple drug regimens for treating PDAC, the 5-year survival rate for patients with PDAC is only 6% 2 . Large-scale genomics studies demonstrate patient-specific variations in genetic and epigenetic changes, highlighting the need to use fresh patient tumor material to evaluate or discover therapies that can be administered on a personalized basis 24 . 
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We analyzed organoids derived from five independent patient tumors: UHN6, UHN17, UHN3, UHN5 and UHN15. All cultures showed poor response to the chemotherapy drug gemcitabine, the current standard of care for PDAC, with an average of 30% growth inhibition (Fig. 6e) . As all patients had undergone surgery between November 2014 and February 2015 and were alive without evidence of disease at time of manuscript preparation, we cannot relate organoid response to gemcitabine with patient outcome.
We next tested the five tumor organoid models against drugs targeting epigenetic regulators. Among the inhibitors tested with progenitor organoids (Supplementary Table 3) , we found that the least toxic were A366, an inhibitor of the histone methyltransferase G9a, and UNC1999, which inhibits EZH2 (a 'writer' of trimethylation of histone H3 at Lys27 (H3K27me3)), (data not shown); thus we selected these for further study. We treated tumor organoids with A366 or UNC1999 alone or in combination with gemcitabine. Tumor organoids were insensitive to A366 (Supplementary Fig. 5a ), but four of five tumor organoids, UHN17, UHN3, UHN5 and UHN15 (but not UHN6), showed a dose-dependent decrease in proliferation when treated with a combination of gemcitabine and UNC1999 (Fig. 6f) . UNC1999 alone suppressed proliferation of UHN17, UHN3 and UHN5 (but not UHN6 or UHN15), suggesting EZH2 dependency in the former group (Fig. 6g) . As expected, the matched tumor and organoids of UHN17, UHN3 and UHN5 positive for the H3K27me3 mark, whereas UHN6 and UHN15 were not (Fig. 6h and Supplementary Fig. 5c ). UNC1999 suppressed H3K27me3 in UHN17 organoids at concentrations showing substantial growth-inhibitory effects (Supplementary Fig. 5b) .
Recent studies reveal a relationship between oxygenation and regulation of H3K27me3 epigenetic marks 25, 26 . Furthermore, cells contributing to PDAC relapse show high dependence on oxidative phosphorylation 27 . We measured basal respiration rates to investigate differences in tumor organoid oxygen consumption. UHN17, UHN3 and UHN5 showed 2-to 3-fold higher normalized basal oxygen consumption rates than did UHN6 and UHN15 organoids (Fig. 6i) . Increased oxygen consumption was suppressed by UNC1999 in UHN17 and UHN3, suggesting a relationship between epigenetic status and oxygen consumption. UHN6 and UHN15 organoids and matched tumors also differed in expression of the hypoxia marker GLUT1 (Fig. 6j) . Thus tumor organoids retain patient-specific traits, including repressive epigenetic marks, oxygen consumption and EZH2 dependence, highlighting the utility of this system for drug screening.
DISCUSSION
We report conditions for inducing human PSC differentiation to pancreatic exocrine lineage organoids and use these organoids to obtain clinically relevant insights into PDAC. We also adapt the approach for establishing and propagating primary PDAC tumors as organoids that maintain tumor-specific traits and show differential responses to novel therapeutic drugs. 
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Previous reports have used mouse pancreas tissue progenitors to develop organoid cultures of ductal cells, which can be manipulated and transplanted in vivo [4] [5] [6] 28 . We report conditions for differentiation of human PSCs toward exocrine lineage in culture and in vivo. Among the pathways associated with pancreas development, we found that TGF-β and notch inhibition facilitated differentiation into ducts and acini, whereas Hedgehog inhibition and Wnt activation at stages 2 and 3 of induction redirected the developmental program away from the pancreatic lineage (data not shown). Further studies with this model will facilitate a better understanding of human pancreatic exocrine differentiation, which has implications for regenerative medicine.
Progenitor organoids can identify genotype-phenotype relationships in PDAC. For example, TP53 R175H , but not KRAS G12V , induces cytosolic SOX9 localization. Using two cohorts of human PDAC samples, we have validated the correlation between cytosolic SOX9 and mutant TP53 status. Although the mechanistic relationship between TP53 and SOX9 localization remains unknown, it highlights the utility of progenitor organoids. Although this model can provide insights into early lesions, our KRAS G12V -induced lesions do not contain luminal space, precluding an evaluation of changes in nuclei position associated with PanINs. To the best of our knowledge, the effects of TP53 mutations in wild-type KRAS human PanINs are not known, hence the significance of our TP53 R175H histopathology for human PanINs warrants further investigation.
We also report conditions that support tumor organoid growth from surgical resections of PDAC with high efficiency (>80%). A recent study reported a method to establish tumor organoids that have histological features consistent with low-grade PanINs, despite npg being derived from adenocarcinoma 28 . In contrast, our conditions promote histostasis, where the organoids conserve inter-patient variation in tumor histoarchitecture, and maintain the differentiation status observed in the matched primary tumor. PDAC organoids have been used for 'omics' approaches to compare mouse and human tumors to gain insights 28 . We demonstrate the use of clonally derived organoids to identify patient-specific sensitivities to novel therapeutic agents. Organoids from different patients showed differential sensitivity to EZH2 inhibition, which correlated with H3K27me3 in both tumor organoids and matched patient tumors. The relatively short time required to establish organoid cultures from the time of surgery (21-45 d) minimizes culture-induced genetic drift and is hence likely to better represent the primary tumor than established cell lines. This suggests organoids may be used to predict clinical responses and personalize cancer treatments.
METHODS
Methods and any associated references are available in the online version of the paper. Mammary gland injection. Day 16 pancreatic progenitor organoids were treated with collagenase/dispase (Roche) and subsequently with accutase for 45 min at 37 °C. Dissociated cells were resuspended with PTOM and 50% Matrigel (5 × 10 7 cells/ml) and kept on ice. Cells (0.3 million-0.5 million) were injected into one mammary gland, and no. 4 and no. 9 glands of 6-to 8-week-old female NOD SCID mice were used for injection. Standard animal care was provided during and after surgery, following the animal user protocol approved by the Animal Care Committee at UHN. Growth of transplants was monitored every week beginning at 4 weeks after injection. No randomization was used, but analyses were conducted in a blinded manner by three separate investigators. For monitoring of in vivo tumorigenesis of progenitor organoids expressing oncogenes, progenitors were lentivirally transduced and cultured in 3D for 16 d as described above. Then progenitor organoids were injected into mouse mammary glands and monitored as described above.
Tumor xenograft model. Passage 3 tumor organoids were cultured in 3D for 16 d then isolated and dissociated by enzymatic digestion. Cells from tumor organoids were resuspended in POTM with 50% Matrigel at a density of 10 5 cells per milliliter. 50,000 cells were subcutaneously injected in the flanks of 6-week-old female NSG mice following a protocol approved by Animal Care Committee, University Health Network. Both flanks of mice were injected, and standard animal care was provided during and after surgery. Growth of transplants was monitored every week from 2 weeks after injection. Xenograft tumors were isolated 4-7 weeks after injection and reseeded in 3D following the protocol described above.
Statistical analysis.
Data from quantitative PCR (qPCR) experiments and MTT proliferation assay were analyzed by two-tailed t-test in Excel. All error bars indicate s.d. unless otherwise stated. Organoid size and shape measurements were analyzed by t-test in GraphPad Prism. Patient survival data were analyzed using a univariate Cox proportional hazards model in R. Supplementary  Figures 1, 2, 4 and 5 can be found in Supplementary Data Set 1.
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